A recent trickle of mergers and acquisitions (M&A) announcements in the billion-dollar-and-up range suggests that biopharma may be ready to resume dealmaking this year—although the value and number of deals isn’t expected to return to the highs seen just before the pandemic. “We expect this to be a more active year as the sentiment starts to normalize a little bit,” Subin Baral, EY Global Life Sciences Deals Leader, told GEN Edge. Baral is not alone in foreseeing a comeback for biopharma M&A.
Read the full article: EY Eyes Comeback for Biopharma M&A //
Source: https://www.genengnews.com/financing/ey-eyes-comeback-for-biopharma-ma